Last reviewed · How we verify
CNG Chemotherapy
CNG Chemotherapy is a Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Cancer (specific indication not clearly defined in available sources). Also known as: Chemotherapy strategy for experimental group.
CNG is a chemotherapy regimen combining multiple cytotoxic agents to inhibit cancer cell proliferation and induce apoptosis.
CNG is a chemotherapy regimen combining multiple cytotoxic agents to inhibit cancer cell proliferation and induce apoptosis. Used for Cancer (specific indication not clearly defined in available sources).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CNG Chemotherapy |
|---|---|
| Also known as | Chemotherapy strategy for experimental group |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CNG typically refers to a combination chemotherapy regimen, though the exact agents are not clearly defined in available literature. Combination chemotherapy works by using multiple drugs with different mechanisms of action to target cancer cells at various phases of the cell cycle and overcome drug resistance. The synergistic effect of multiple agents often improves efficacy compared to single-agent therapy.
Approved indications
- Cancer (specific indication not clearly defined in available sources)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Mucositis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNG Chemotherapy CI brief — competitive landscape report
- CNG Chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about CNG Chemotherapy
What is CNG Chemotherapy?
How does CNG Chemotherapy work?
What is CNG Chemotherapy used for?
Who makes CNG Chemotherapy?
Is CNG Chemotherapy also known as anything else?
What development phase is CNG Chemotherapy in?
What are the side effects of CNG Chemotherapy?
Related
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer (specific indication not clearly defined in available sources)
- Also known as: Chemotherapy strategy for experimental group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing